Prof Michael Herbst of CANSA was interviewed on SABC TV on the question of the exorbitant costs of cancer medications and the announcement by the Competition Commission of its probe into the pricing of several cancer medicines in South Africa.
Watch this short interview here.
Related
For overpricing bone marrow cancer drug The Competition Commission has referred for prosecution to the Competition Tribunal (“Tribunal”), international drug manufacturer Celgene Corporation (“Celgene Corp”) and its subsidiary Celgene Logistics S.a.r.l (“Celgene...
Represented by SECTION27, takes on multinational company Cancer Alliance tackles price gouging 14 November 2024, Johannesburg - The Cancer Alliance, represented by SECTION27, has been admitted by the Competition Tribunal as an intervening party in the excessive...
Access to Medicine: Lenalidomide Cancer Alliance submitted a case for the investigation of excessive pricing for lenalidomide to the South African Competition Commission in January 2023. The CompCom confirmed their intention to investigate this case in February 2023....
